Abstract Mitocans are drugs selectively killing cancer cells by destabilizing mitochondria and many induce apoptosis via generation of reactive oxygen species (ROS). However, the molecular events by which ROS production leads to apoptosis has not been clearly defined. In this study with the mitocan a-tocopheryl succinate (a-TOS) the role of the Bcl-2 family proteins in the mechanism of malignant cell apoptosis has been determined. Exposure of several different cancer cell lines to a-TOS increased expression of the Noxa protein, but none of the other proteins of the Bcl-2 family, an event that was independent of the cellular p53 status. a-TOS caused a profound conformational change in the pro-apoptotic protein, Bak, involving oligomerization in all cell types, and this also applied to the Bax protein, but only in non-small cell lung cancer cells. Immunoprecipitation studies indicated that a-TOS activates the two BH1-3 proteins, Bak or Bax, to form high molecular weight complexes in the mitochondria. RNAi knockdown revealed that Noxa and Bak are required for a-TOS-induced apoptosis, and the role of Bak was confirmed using Bak-and/or Bax-deficient cells. We conclude that the major events induced by a-TOS in cancer cells downstream of ROS production leading to mitochondrial apoptosis involve the Noxa-Bak axis. It is proposed that this represents a common mechanism for mitochondrial destabilization activated by a variety of mitocans that induce accumulation of ROS in the early phases of apoptosis.
Introduction a-Tocopheryl succinate (a-TOS) is a tumor-selective drug activating intrinsic apoptosis [1, 2] by targeting the mitochondrial complex II (CII; succinate dehydrogenase) triggering subsequent production of reactive oxygen species (ROS) [3, 4] . The importance of ROS accumulation in apoptosis induction by a-TOS was established in that higher levels of apoptosis in cancer cell lines were directly associated with greater ROS production [5] . In addition, antioxidants, such as the mitochondrially targeted coenzyme Q, suppressed the anti-cancer cell toxicity of the vitamin E (VE) analog [6, 7] .
Several mechanisms have been suggested to explain a-TOS induced apoptosis, mostly involving mitochondrial destabilization [8] . It has also been reported that the VE analog acts as a Bcl-2 homology-3 (BH3) mimetic, since it interacted with the BH3 domain of the Bcl-2 family proteins, disrupting the interaction between Bak, Bcl-x L and Bcl-2 in prostate cancer cells [9] . Another report suggested a-TOS induced translocation of Bax into mitochondria in breast cancer cells, although the mechanism of this process was not defined [10] . These results led to the proposal that ROS production induced the dimerization of Bax, followed by its mitochondrial mobilization [11] , perhaps helping to explain the events occurring in a-TOS-challenged cells [8, 12] . However, the precise mechanisms of mitochondrial translocation and/or activation of apoptogenic Bcl-2 family proteins triggered by a-TOS remained unclear.
A hallmark of mitochondrial apoptosis is the permeabilization of the mitochondrial outer membrane (MOM) involving two Bcl-2 protein family members, the BH1-3 domain proteins, Bak and Bax with at least one of these two proteins shown to be necessary for pore formation in the MOM [13] [14] [15] . In most cases, MOM permeabilization is triggered by activation of BH1-3 proteins, either by increasing their expression or via the BH3-only proteins Noxa, Puma, Bim, or Bid. It has been proposed that the BH1-3 proteins are liberated from their heterodimeric association with members of the pro-survival Bcl-2 family or they can be directly activated [16] [17] [18] . From this point of view, it is of interest that a-tocopheryloxyacetic acid (a-TEA), an ether analog of VE, was previously shown to kill breast cancer cells via a pathway involving upregulation of the BH3-only protein, Noxa [19] .
Activation of the Bak and Bax proteins corresponds to conformational changes, which involve exposure of the N-terminus of these proteins [20, 21] and their subsequent oligomerization in the MOM [22] . ROS-dependent dimerization of Bax protein via disulfide bond formation has also been proposed as one mechanism for Bax activation [11] . According to another hypothesis, the BH1-3 proteins may polymerize at their ends or interact with lipids of the MOM, with ensuing MOM destabilization or lipid pore formation [13, [23] [24] [25] . In addition to Bax and Bak, the BH1-3 domain protein, Bok (also known as Diva) can also cause MOM permeabilization. However, since Bok is restricted to a small number of malignant tissues, it is irrelevant for most types of cancer cells [26] .
Because individual types of cancers are complex and can differ considerably in their array of DNA mutations, harboring different sets of genetic changes [27, 28] , it will be very unlikely to cure cancer with drugs targeted to only a few gene products or single pathways involved in tumor survival [29] . The importance of mitocans, epitomized by VE analogs (in particular the prototypic a-TOS), as anticancer agents that target mitochondria to trigger apoptosis [3, 4, 8, 12] is that mitochondrial function is a universal cellular requirement. Thus, mitochondria are prime targets and transmitters of apoptosis which if selectively activated in cancer cells would provide an effective treatment for a variety of different tumors. It is this imperative which makes it critical to understand in greater detail the molecular mechanisms by which VE analogs cause permeabilization of the MOM, a paradigm that may be utilized for efficient therapy of many different cancers [30, 31] .
Materials and methods

Cell culture and treatment
Jurkat T lymphoma cells, the Bak -/Bax -and Bax -Jurkat cells [32] , the p53-deficient H1299 non-small cell lung cancer cell line [33] , as well as the MCF7 breast adenocarcinoma cell line and its p53-transcriptionally inactive sub-line (MCF7 DD9 ) [34] were grown in RPMI-1640 medium supplemented with antibiotics and 10% FBS. Jurkat cells were treated with a-TOS (Sigma) (for structure see Fig. 1 ) at 5 9 10 5 cells per ml, and the adherent H1299, MCF7 and MCF7 DD9 cells at 80-90% confluency. a-TOS was always freshly prepared in ethanol as a stock solution that was added to the cell cultures so that the concentration of ethanol in the medium did not exceed 0.1% (v/v). In some cases, the cells were pre-incubated (1 h) with 1 lM mitochondrially targeted coenzyme Q (MitoQ; for structure, see Fig. 1 ) [35] . were all from Santa Cruz; anti-Bcl-x L IgG, anti-Bim IgG, anti-Cox IV IgG and anti-Puma IgG were from Cell Signaling).
To obtain whole cell lysates, cells were centrifuged at 300 9 g for 5 min and washed twice with ice-cold PBS. The pellet was resuspended in whole cell lysis buffer (10 mM TRIS at pH 7.4, 1 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 0.1% SDS, 1% Triton X-100, plus protease inhibitor cocktail), frozen, thawed and sonicated. Aliquots were used to estimate the level of total protein using the BCA method (Pierce). The samples were then diluted in loading buffer and boiled for 4 min. Proteins were resolved by SDS-PAGE and transferred to PVDF or nitrocellulose membranes (GE Healthcare). After probing with a specific primary antibody and horseradish peroxidase-conjugated secondary antibody, the bands were detected by the enhanced chemiluminiscence (ECL) kit or the Advanced ECL kit (both GE Healthcare) using either a gel documentation system (Bio-Rad) or X-ray film (AGFA).
Isolation of mitochondria and gel filtration chromatography Cells (1.2 9 10 8 ) were left untreated or treated with an appropriate concentration of a-TOS, human recombinant TNF-related apoptosis-inducing ligand (TRAIL) [36] or staurosporine (STS) for different periods, harvested and washed twice with ice-cold PBS. The final pellet was resuspended in 500 ll of ice-cold hypotonic fractionation buffer (25 mM Tris at pH 7.4, 2 mM EDTA, 5 mM MgCl 2 , 10 mM KCl, 125 mM sucrose, 1 mM PMSF, plus protease inhibitor cocktail), and left on ice for 10 min. The swollen cells were broken using a glass homogenizer (Kontes Glass Co.). The isotonicity of each sample was achieved by addition of 250 ll of ice-cold hypertonic fractionation buffer containing 500 mM sucrose. Organelles and unbroken cells were centrifuged at 900 9 g for 10 min, followed by centrifugation of the supernatant at 1,700 9 g for 5 min. The remaining supernatant was then centrifuged at 15,000 9 g for 10 min and the mitochondrial pellet lysed in a buffer comprising 25 mM HEPES, pH 7.5, 300 mM NaCl and 2% CHAPS. The mitochondrial lysate was centrifuged at 19,000 9 g for 5 min and loaded onto the Superdex-200 10/300 Preparation Grade column (Amersham Biosciences). The column was equilibrated with the 2% CHAPS lysis buffer (see above). The proteins were eluted at 0.3 ml/min, and fractions of 0.5 ml were collected and mixed with 3-times concentrated Laemmli reducing sample buffer and boiled. The samples were then analyzed by SDS-PAGE and western blotting.
Assessment of apoptosis and ROS accumulation
Apoptosis was evaluated by flow cytometry (FACS Calibur, BD Bioscience) using the annexin-V FITC and propidium iodide method, essentially as described [2] . ROS accumulation was assessed using the fluorescent probe dihydroethidium (DHE) essentially as detailed elsewhere [2] .
Analysis of Bak and Bax conformational changes
Drug-induced exposure of the N-terminus of Bak was assessed using the epitope-specific antibody directed against the amino acid sequence 1-57 of the Bak protein (clone Ab-1) [37] . The active conformation of Bax was estimated using anti-Bax IgG (clone 6A7) directed against amino acids, 12-24, which only cross-reacts with the active/mitochondrially localized Bax protein domain [20] . Cells grown in a 6-well plate were exposed to various concentration of a-TOS, STS (positive control for inducing Bak and Bax conformational changes) [37, 38] or TRAIL, after which they were harvested, washed with ice-cold PBS, and fixed with 0.25% paraformaldehyde. The cells were then washed with ice-cold PBS and incubated with primary antibody diluted 1:50 in digitonin (100 lg/ml of PBS) for 30 min, which was followed by a 30 min incubation with an FITC-labeled secondary antibody diluted 1:75 in digitonin-PBS, and analyzed by flow cytometry using 'live gating' to exclude cellular debris.
Immunoprecipitation
Pelleted mitochondria were resuspended in 1 ml of immunoprecipitation lysis buffer (1% CHAPS, 150 mM NaCl, protease inhibitors cocktail, 25 mM HEPES, pH 7.4), left on ice for 30 min before centrifugation at 16,000 9 g for 3 min. A 20 ll aliquot of the supernatant was used for the BCA protein level assay while the rest of the lysate was pre-cleared with 1 ll of mouse serum (protein concentration 4 mg/ml) and 20 ll of Protein G-conjugated agarose beads (Santa Cruz) at 4°C for 30 min. The Protein G agarose beads with the bound immunoglobulins were spun down at 1,000 9 g for 5 min and the remaining supernatant comprised pre-cleared lysate. The lysate was then diluted to the final protein concentration of 300 lg/ml. A 1 ml aliquot of the lysate was incubated with 2 lg of mouse monoclonal anti-Mcl-1 or rabbit polyclonal anti-Bcl-x L or anti-Bim IgG at 4°C for 3 h under gentle agitation followed by addition of 20 ll of Protein G-conjugated agarose beads and incubated overnight at 4°C. The Protein G beads were then pelleted at 1,000 9 g for 5 min, washed 4 times with the immunoprecipitation lysis buffer, resuspended in 40 ll of 1.5 times concentrated reducing sample loading buffer and boiled for 5 min. The samples were then centrifuged to remove the Protein G beads and the supernatant was loaded onto a gel for SDS/PAGE. Co-immunoprecipitated proteins bound to Mcl-1, Bcl-x L or Bim were detected using specific antibodies and western blotting. Pure lysis buffer handled in parallel with the real samples, pre-cleared and containing antibodies was used as a negative control.
Quantitative real-time PCR Total RNA was extracted with the TRI reagent (MRC) and reverse-transcribed to cDNA using oligo dT primers and the M-MLV reverse transcriptase (Invitrogen). Quantitative real-time PCR (Q-PCR) was performed using the LightCycler 480 instrument (Roche) operated using 95°C for 15 min; 50x: 95°C for 15 s, 58°C for 30 s, 72°C for 30 s and melting analysis was performed from 60 to 95°C. Each PCR reaction mixture of 10 ll contained 5 ll of the SYBRgreen Master Mix (Invitrogen), 0.5 ll cDNA, and forward and reverse primers at the concentration of 0.8 lM. Relative quantification of target genes expression was performed using the formula described elsewhere [39] . RNA interference H1299 and MCF7 cells were modified by silencing the expression of the Noxa, Bim, Mcl-1, Bax and Bak proteins using short interfering RNA (siRNA) essentially as described elsewhere [40] . In brief, cells were grown at 30% confluence in the absence of antibiotics and incubated with individual siRNAs pre-incubated with Lipofectamine-2000-supplemented OptiMEM medium. Bak siRNA, Bim siRNA and Mcl-1 siRNA (Ambion), and Bax siRNA (Santa Cruz Biotechnology) were used at 60 nM, Noxa siRNA (Santa Cruz Biotechnology) at 20 nM and the control (scrambled) siRNA (Santa Cruz Biotechnology) at 20 or 60 nM. After 7 h, the OptiMEM medium was replaced with complete RPMI medium without antibiotics. After an additional 24 h, the cells were transferred into a 96-well flat bottom test plate or into 12-well plates and grown for another 24 h, and assessed for the levels of individual proteins and for cytotoxicity induced by a-TOS.
MTT cytotoxicity test
The MTT colorimetric assay [41] was used to assess the cytotoxic effects of a-TOS on siRNA-transfected cells. MTT (Sigma) was dissolved in PBS at 2.5 mg/ml and sterile-filtered. 20 ll of the MTT solution were added into each well of the 96-well plate with siRNA-transfected cells treated with various concentrations of a-TOS for 24 h. The plates were then incubated at 37°C in 5% CO 2 for 3 h, 100 ll of 10% SDS was then added into each well, and the plates were then stored overnight in the dark at room temperature, after which they were analysed for absorbance at 540 nm using a microplate reader (Synergy II; Biotek). All experiments were performed in triplicate. The value of IC 50 and the 95% confidence interval of the mean were calculated using GraphPad PRISM 5.00 software (GraphPad Software) and non-linear regression to establish doseresponse inhibitory curves. The data sets were compared by Extra sum-of-squares F test based on traditional statistical hypothesis testing.
Statistics
The acquired data, unless otherwise stated, were analyzed using the GraphPad PRISM 5.00 software. The data represents the mean ± SEM of three independent experiments. The symbol '*' denotes P \ 0.05. Images are representative of at least three independent experiments.
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Results
We had previously shown that cancer cells treated with a-TOS died independently of their p53 status as exemplified by the p53 -/-HCT116 colorectal carcinoma cell line [36] . These studies have been extended here to p53 null cancer cells of different origin confirming that the p53 protein is redundant for apoptosis induced by the VE analog (Fig. 2) . For these studies, the cell lines expressing wild type p53 protein included Jurkat (T lymphoma) and MCF7 (breast carcinoma) cell lines, whereas the non-small cell lung carcinoma cell line, H1299, is p53-deficient and the breast carcinoma cell line, MCF7 DD9, has a transcriptionally silent p53. a-TOS induced apoptosis at concentrations ranging between 50 and 80 lM within 24 h in all the cell lines tested, with only slight differences in the capacity of a-TOS towards the p53 null cell lines with all showing cytochrome c release (Fig. 2) .
To obtain a greater understanding of the mechanism leading to activation of apoptosis by a-TOS and the role of mitochondria in the process [2-4, 9, 37, 42-45] , the role of the Bcl-2 family proteins indispensable for apoptosis induction/progression was examined [13, 14] . First, Q-PCR was used to estimate mRNA levels for the pro-and antiapoptotic Bcl-2 family members, including Bax, Bak, Noxa, Puma, Bim, Mcl-1, Bcl-2 and Bcl-x L . The only genes showing a significant response to a-TOS-induced stress with increased mRNA levels were Noxa and Puma (Fig. 3) . We next examined a-TOS-induced protein expression of Noxa and Puma by western blot analysis, which confirmed increased levels of Noxa, but not the Puma protein and no changes in the levels of other Bcl-2 family proteins (Fig. 3) . Importantly, the increase in expression of Noxa occurred independently of the p53 status of the cells, as the single BH3 only member of the Bcl-2 family upregulated in response to a-TOS in both the p53-null H1299 cells and in the MCF7 DD9 cells with transcriptionally silent p53 (Fig. 3) . In the next set of experiments we tested the premise that apoptosis induced by a-TOS and Noxa upregulation are a result of generation of ROS. Further, we tested the possibility that the increase of Noxa expression is downstream of ROS generation. This is suggested by our previous results showing that ROS are generated within 1 h in cancer cells exposed to a-TOS [2, 3, 7] and we documented it in this study by experiments in which MitoQ was used as a scavenger of ROS. Results presented in Fig. 4 document high levels of ROS in Jurkat cells exposed to a-TOS for 1 h, which was suppressed by MitoQ (Fig. 4a) . The ROS scavenger also suppressed apoptosis induction (Fig. 4b) and Noxa protein upregulation (Fig. 4c) . These results therefore support a causal relationship in a-TOS-challenged cells between early ROS accumulation, Noxa upregulation and apoptosis induction.
Since Noxa protein upregulation is accepted as one of several possible cellular processes that precede MOM permeabilization [17] , pore formation was examined. Before the MOM pore can be formed, its components (usually Bak and/or Bax) must be conformationally activated. In accordance with earlier reports [20, 37, 38] , flow cytometry of permeabilized cells using antibodies directed against epitopes exposed on the surface of 'activated' Bax and Bak proteins can be utilized to assess the extent of conformational changes of Bak and Bax proteins in individual cell lines. STS (0.5 lM) was used as a positive control for the activation of Bak and Bax proteins in Jurkat cells, and TRAIL (250 ng/ml) was used for similar purposes in the other cell lines [45] . All the cell lines tested in this study responded to a-TOS treatment by undergoing conformational changes in Bak protein, whereas the Bax conformation remained unchanged in Jurkat cells, was slightly altered in MCF7 and was highly modified in H1299 cells (Fig. 5) . The observed conformational changes of Bax protein were not regulated by p53, since we observed prominent activation of the protein in the p53-null H1299 cells and only slight changes in the MCF7 DD9 cells with transcriptionally silent p53 (Fig. 5) .
Given the conformational changes detected in Bak protein from all cell lines tested and in Bax protein from some of the cell lines, we next investigated the extent of oligomerization of Bak or Bax in response to a-TOS. Gel filtration chromatography and mild buffer conditions were used to separate purified mitochondrial lysates from control cells and cells treated with the VE analog using a Superdex-200 column to separate macromolecules from 3 to 600 kDa. Individual fractions were collected and analyzed by western blotting for the presence of anti-Bak IgG-and anti-Bax-IgG-reactive proteins. In agreement with the results above showing conformational change (Fig. 5) , we observed anti-Bak IgG-reactive proteins in high molecular weight (HMW) fractions in all cell lines studied following their exposure to a-TOS, whereas only H1299 cells showed anti-Bax IgG-reactive proteins in HMW fractions when exposed to the VE analog (Fig. 6) . Further, we observed very weak Bax-positive bands in the HMW fractions from mitochondrial lysates of MCF7 and MCF7 DD9 cells (Fig. 6) , consistent with low levels of conformational change detected in these cells (Fig. 5) . The results show that mitochondria from cells treated with a-TOS, as well as with TRAIL or STS contain significant amounts of Bak protein in HMW fractions of up to 260 kDa. In the control cell samples, Bak protein was present only in the low MW fractions (50-80 kDa), consistent with the proposal that Bak remains functionally inactive, bound in heterodimeric complexes with Mcl-1 or Bcl-x L in these cells [17] . On the other hand, Bax protein was detected in HMW fractions in the cell lines (except for H1299 cells) only after treatment with TRAIL or STS. Bax protein in its inactive state largely resides in the monomeric form in the cytosol. However, initial analysis of fractions of mitochondrial lysates from non-treated and a-TOS treated cells did not contain sufficient Bax protein present to allow detection using standard ECL reagents. Consequently, Advanced ECL detection kits were used and with greater sensitivity revealed the presence of the Bax protein in the low MW fractions corresponding to 20-50 kDa in control cells as well as in a-TOS-treated cells. These low MW forms likely correspond to either the monomeric form of Bax loosely attached to the mitochondrial membrane or the heterodimer in complex with anti-apoptotic members of the Bcl-2 family.
The above results indicated a prominent role for the Bak protein in a-TOS-induced cell death. Next, the a-TOS induced increase in levels of Noxa was examined for its role in Bak channel formation leading to apoptosis. For these studies, samples of mitochondrial lysates prepared from a-TOS-treated or control H1299 cells were immunoprecipitated with antibodies against the anti-apoptotic Bcl-2 family protein Mcl-1 or Bcl-x L , both of which are known to interact with BH1-3 and BH3-only proteins. The Noxa protein was found to co-immunoprecipitate with Mcl-1 in samples from a-TOS-treated cells but not control cells (Fig. 7) . No Noxa protein was detected in the Bcl-x L immunoprecipitates. Surprisingly, the amount of Bak protein co-immunoprecipitated with Mcl-1 was significantly higher in a-TOS-treated cells than in the control cells (Fig. 7) . A similar or even greater difference between treated and non-treated cells was observed in Bcl-x L immunoprecipitates, where the amount of associated Bak was also higher in a-TOS treated cells. Moreover, Bcl-x L was also co-immunoprecipitated with Bax protein from treated cells and not from the control cells. Bim, as another BH3 protein of interest was analyzed for its interaction following a-TOS treatment and was found associated with Bak, but not Bax after a-TOS treatment (Fig. 7) . The two splice variants of Bim protein, BimEL and BimL, were detected in the mitochondria of the treated cells at significantly greater levels than in control cells (Fig. 7) . From these results, it is concluded that a-TOS upregulates the Noxa protein that binds Mcl-1 and also causes translocation of Bim into mitochondria that together leads to activation of Bak to form pores in the MOM. Although the results presented above documented the involvement of the Noxa-Bak axis in apoptosis [46] induced in various cancer cell lines by a-TOS, more definitive evidence was sought identifying the role of the BH3 proteins. For this, use was made of Bax -/Bak -Jurkat cells as well as those lacking only the Bax protein. Exposure of these cells as well as their Bax/Bak-proficient counterparts revealed that Bax -/-and the parental Jurkat cells were equally susceptible to a-TOS-induced apoptosis, while the Bax -/Bak -cells were resistant, at least over the first 24 h of treatment. Similar observations were made when the three different Jurkat cell lines were exposed to TRAIL (Fig. 8) , consistent with a previous report [47] . While these results confirm the importance of Bak and/or Bax proteins for fast induction of apoptosis, we observed delayed cell death in the Bax -/Bak -cells (Fig. 8) . The nature and the molecular mechanism of the delayed death of the double-deficient cells are unclear at this stage and under investigation in our laboratory.
To further determine the roles of Bcl-2 proteins in apoptosis induced in cancer cells by a-TOS, RNA interference (RNAi) was used to knock down expression of proteins of interest and the resulting change in the IC 50 values for cellular responses to a-TOS in the RNAi-treated cells assayed using MTT. Exposure of cells to individual siRNA duplexes resulted in substantially reduced levels of the targeted proteins, i.e. Bak, Bax, Bim, Noxa and Mcl-1 (Fig. 9a) . Downregulation of the Bak protein in MCF7 cells shifted the 24 h IC 50 value from *65 to *100 lM (Fig. 9b) and the 40 h IC 50 value from *45 to *70 lM (data not shown). Combining Bak and Noxa siRNA treatment or using either siRNA alone produced similar effects in the H1299 cells becoming more resistant to a-TOS (Fig. 9c) . Knocking down Bax had no effect on the susceptibility of the cells to a-TOS (Fig. 9c) . Surprisingly, downregulation of Bim did not yield statistically significant difference in 24 h IC 50 . Importantly, downregulation of the anti-apoptotic Mcl-1 protein significantly increased susceptibility of H1299 cells to a-TOS (Fig. 9c) . These results confirm the importance of the Noxa-Bak-Mcl-1 axis in apoptosis induced in cancer cells by a-TOS.
Discussion
Redox-silent VE analogs epitomized by the prototypic a-TOS belong to the anti-cancer drugs termed 'mitocans' [1, 8, 48] which induce apoptosis in cancer cells, often in a selective manner by mitochondrial destabilization. Mitocans comprise 8 groups of compounds that destabilize mitochondria by utilizing different mechanisms [48, 49] . We have placed VE analogs into group 2 [9] , containing BH3 mimetics, and group 5 comprising agents interfering with the electron redox chain [3, 4] . We and others have documented that VE analogs cause high level accumulation of ROS in the early stages of apoptosis [2-7, 42, 44, 50] leading to mitochondrial destabilization, involving regulation of the Bcl-2 family proteins [2, 10, 51] . However, the precise molecular bases for the link between ROS accumulation and mitochondrial destabilization have not been identified. Although many inducers of apoptosis cause ROS accumulation followed by pore formation in the MOM, surprisingly, how these events link together has until now not been clear [52] . In this study, the role of the Bcl-2 family proteins in permeabilization of the MOM during a-TOS-induced apoptosis of cancer cell lines has been determined. Results with different wild-type and inactive p53 cancer cells were consistent and extended our previous findings that the VE analog induced apoptosis independently of the p53 status in the HCT116 colon cancer cell line [36] . Recently, it was reported that a-TEA, an ether analog of a-TOS, also induced apoptosis independently of p53, by upregulating the BH3-only protein Noxa, although the precise mechanism of MOM formation was not determined [19] . We show here that a-TOS causes increased expression of the Noxa and Puma mRNA, both independently of p53. However, only the Noxa gene is upregulated at the protein level, while that of Puma is not increased, indicating possible differences in the post-transcriptional regulation of the Noxa and Puma proteins. Although Puma upregulation at the mRNA and not protein level to the best of our knowledge has not been reported before, the underlying mechanism for these events will require further studies.
The 'indirect model' [17] for pore formation in the MOM involving the Bcl-2 family proteins proposes a role for BH3-only proteins (e.g. Noxa, Puma, Bim), in apoptosis induction in eukaryotic cells, that are upregulated leading to the activation by subsequently displacing and liberating the pro-apoptotic Bak or Bax proteins from their complexes with anti-apoptotic Bcl-2 family members (such as Bcl-2, Bcl-x L or Mcl-1). The Mcl-1 protein, which lacks the BH4 domain but contains a PEST sequence, has been proposed to undergo proteasomal degradation in the course of liberating Bak and/or Bax proteins that then form pores in the MOM [53, 54] . However, the results presented here suggest that degradation of the Mcl-1 protein following Noxa upregulation did not occur in any of the cell lines tested. These results are similar to those from other studies documenting that the Mcl-1 protein does not need to be degraded in order to be functionally inactivated during the apoptotic process. For example, this has been reported for apoptosis induction by campthotecin involving Noxa upregulation in H1299 and HeLa cells [55] , Bim-induced apoptosis in MCF7 cells [56] , c-secretase inhibitor GSIinduced apoptosis in HCT116 cells [46] , or the proteosomal inhibitor bortezomid in B-cell lymphoma [57] .
It was proposed that destabilization of the Mcl-1 protein may involve its JNK-dependent phosphorylation [58] . We tested this premise in our system using the JNK inhibitor SP600125. Since we found that this did affected a-TOS-induced apoptosis in neither Jurkat nor H2199 cells (data not shown), we did not pursue this pathway any further in our studies.
Co-immunoprecipitation of Mcl-1 complexed with Noxa or Bak, Bcl-x L with Bak and of Bim with Bak in H1299 cells showed that Mcl-1/Noxa and, rather surprisingly, Mcl-1/Bak and Bcl-x L /Bak interactions were more abundant in the a-TOS-treated than in the control cells. This kind of result was very surprising, since co-IP experiments of this type of proteins usually give opposite results. Explanation of this, however, may lie in the definition of the 'direct model' for Bax and Bak activation [18, [59] [60] [61] . Central to this model is the concept that Bak and Bax sequestered by the anti-apoptotic Bcl-2 proteins represent only a fraction of the total Bak and Bax protein pools when these pro-apoptotic proteins are activated either spontaneously or by some unspecified mechanisms [18, 62] . Co-immunoprecipitation experiments presented here indicate that a-TOS-induced activation of Bak and Bax may cause their sequestration by Mcl-1 and Bcl-x L , respectively, until a saturation point is surpassed allowing accumulation of the active forms of Bak and Bax. Moreover, the Noxa protein, upregulated by treating cancer cells with a-TOS not only could compete with activated Bak for the hydrophobic BH3 binding groove of Mcl-1 [63] or Bcl-x L [64] making Bak freely available, but could also possibly displace Bim from its complex with Mcl-1, allowing Bim to act as a direct co-activator of Bak or Bax [46] . Unexpectedly, we did not detect any interaction between Bim and Mcl-1, although Bim accumulated in mitochondria and interacted with the Bak protein, which was the first time observed (and also tested in H1299 cells) direct interaction of the wt Bim and Bak protein to the best of our knowledge. The co-IP results suggest that increased level of the Bim protein associated to the mitochondria of a-TOS treated H1299 cells probably directly relates to the increased number of the Bak protein detected in co-IP WB. a-TOS perhaps aims Bim at mitochondria without any other direct effect on the self-interaction of Bim and Bak. Similarly, Noxa does not seem to disrupt, at least in our study in H1299 cells, the pre-formed anti-apoptotic Bak/ Mcl-1, Bak/Bcl-x L or even Bax/Bcl-x L complexes and rather competes with the BH1-3 proteins for the Mcl-1 protein.
The results obtained in this study better fit a model where the excessive unsequestered monomers of activated Bak protein (and Bax protein in the case of H1299 cells), are then free to self-interact, forming a pore triggering the apoptotic cascade downstream of mitochondria. In the case of the non-small cell lung carcinoma H1299 or A549 cells, which express high levels of the Mcl-1 protein, Mcl-1 can significantly prolong the apoptotic process induced by various pro-apoptotic stimuli including cisplatin, etoposide, UV irradiation or calcium ionophores [65] with similar results also shown for hematopoietic cells [66] . We propose that a-TOS sensitizes Mcl-1-overexpressing cells to a variety of pro-apoptotic stimuli, in a similar manner to that shown for cells treated with the topoisomerase I inhibitor CPT-11 which also acted to increase expression of the Noxa protein [67] .
Both the indirect and direct activation models share a common denominator: any major disruption of the dynamic balance between the anti-apoptotic Bcl-2 family proteins and the BH3 pro-apoptotic proteins favoring unsequestration of the latter triggers the intrinsic apoptotic process. It has been published that a conformational change of the BH1-3 proteins is important for aggregation of these proteins and for their targeting to the MOM, where they eventually form a pore that allows the apoptotic cascade to proceed [21, 22] . In this study, we used antibodies recognizing epitopes exposed only on the activated states of BH1-3 proteins. However, the detection of the activation epitope on the Bak protein (documented by using the specific antibody Ab-1) unlike that found for the Bax protein (utilizing the 6A7 antibody) does not necessarily mean that the Bak MOM pore will be formed [20, 21] . Thus the recognition of the N-terminal activation epitope of the Bak protein by the Ab-1 antibody may detect only the 'priming' stage for Bak functional activation. We have observed the activation or 'priming' of Bak in all cell lines tested, and this correlated with the process of a-TOSinduced Bak MOM pore formation. By contrast, the Bax protein was fully activated only in the H1299 cells suggesting a relatively similar importance for these two proteins to mediate a-TOS-induced apoptosis in the non-small cell lung carcinoma cell line. The MCF7 and MCF7 DD9 cells showed only slight levels of Bax activation, occurring after most of the Bak protein had been activated which suggests a higher level of functional importance for the Bak protein in breast cancer cells. After epitope activation or 'priming' of the BH1-3 proteins, they oligomerize due to interaction of activated monomers via their BH3 domains within the MOM, becoming detectable in higher molecular weight fractions of mitochondrial lysates [68] . Our results demonstrate that the Bak protein oligomerizes in mitochondria after a-TOS treatment in all tested cell lines, since it was only then detected in fractions [160 kDa. Our data from FPLC analysis of the mitochondrial lysates of cells treated with a-TOS (Fig. 6) indicate that the Bak protein complexes formed are homo-oligomeric, since Bax protein was not found in these same fractions. Conversely, the results observed in the H1299 cells indicate that the Bax protein oligomers do not contain Bak protein. These observations rule out hetero-oligomerization of the Bak and Bax proteins during cancer cell apoptosis induced by VE analogs.
Our data for Bak oligomerization are consistent with and further explained by recent reports, documenting that following an apoptogenic signal, two Bak monomers initially form a homodimer by way of generation of disulphide bridges, which is followed by higher homo-oligomeric structures that results in formation of a Bak channel in the MOM [69, 70] . We propose that this step occurs following Noxa upregulation in cancer cells exposed to a-TOS, which gives initially higher levels of ROS that themselves not only cause increased expression of the Noxa protein but, following Noxa-mediated departure of Bcl-2 family antiapoptotic proteins from Bak, but also catalyse formation of the Bak-Bak dimers.
Conformational changes of Bak protein has been shown to occur during apoptosis induced by VE analogs in prostate cancer cells via a BH3 mimetic like mode of action [9] . However, we did not observe a similar activity induced by a-TOS in the cell lines used in our experiments. Unlike the report by Shiau and colleagues, who observed disruption of Bak-Mcl-1 or Bak-Bcl-x L interaction in prostate cancer cells treated with a-TOS [9] , we found that the Bak protein did immunoprecipitate with Mcl-1 and Bcl-x L in MCF7 (data not shown) and in H1299 cells exposed to a-TOS. Therefore, the BH3 mimetic-like activity of VE analogs may be cell-type specific, dose related or both. Notwithstanding, we suggest that the BH3 mimetic-like activity of VE analogs should make a significant contribution by sensitizing cancer cells to apoptosis induction by other agents, particularly in cell lines overexpressing the anti-apoptotic Bcl-2 family proteins. However, the major role of VE analogs in apoptosis induction can be ascribed to the accumulation of high levels of ROS in the exposed cells, which translates to mitochondrial destabilization, as delineated in this report.
The requirement of the Bak protein and involvement of Mcl-1/Bak axis in a-TOS-induced apoptosis was confirmed by RNAi against Bak and Mcl-1 while knocking down of the Bax protein did not significantly affect the IC 50 values of a-TOS, at least in H1299 cells. We observed an increase in the IC 50 value in cells exposed to the VE analogue following knock down of the Bak or Noxa protein levels. Probably the most direct evidence for the importance of the Bak protein in apoptosis induced by a-TOS, at least for the Jurkat T lymphoma cells, comes from experiments comparing wild-type cells with cells deficient in both Bak and Bax or either one of these two proteins. The results clearly indicate that Jurkat cells containing the Bak protein are susceptible to apoptosis while the Bax protein appears not to be critical.
We have recently documented that the target of VE analogs is the mitochondrial CII [3, 4, 44] , and this has been supported by others (Gogvadze et al., personal communication). Thus, a-TOS displaces ubiquinone from CII, such that electrons, generated due to conversion of succinate to fumarate at CII [71] , cannot be intercepted and give rise to superoxide [72] . The resulting ROS then cause mitochondrial destabilization by a mechanism that has previously not been clarified. According to the data shown here, we propose a model whereby ROS leads to transcriptional upregulation of the BH3-only protein Noxa that may cooperate with Bim and results in unsequestration, activation and oligomerization of the BH1-3 protein Bak, with ensuing formation of a pore in the MOM. The a-TOStriggered ROS accumulation that causes transcriptional upregulation of Noxa is dependent on the FOXO family of transcription factors and is the subject of ongoing research (K.V. et al., unpublished results).
In conclusion, we document here that redox-silent VE analogs, epitomized by a-TOS, destabilize mitochondria by promoting formation of MOM pores. To the best of our knowledge, this is the first report defining the molecular mechanism triggered by mitocan induced ROS accumulation in cancer cells leading to mitochondrial activated apoptosis.
